How does Polivy work in the body?
Polivy (polatuzumab vedotin) is an antibody-drug conjugate. It works by combining targeted delivery with a cell-killing payload.
It is designed to bind to CD79b, a protein found on the surface of many B-cell lymphomas. After the antibody attaches to CD79b, the drug is pulled into the cancer cell. Inside the cell, the attached toxin is released and then disrupts the cell’s ability to make proteins, leading to cancer-cell death.
What does the “antibody-drug conjugate” part mean?
Polivy has two main components working together:
- A monoclonal antibody that homes in on CD79b on B cells.
- A cytotoxic (cell-killing) small-molecule toxin linked to the antibody, which is released after internalization into the cancer cell.
That structure helps concentrate the toxin in cells that carry CD79b, rather than relying only on conventional chemotherapy’s broader effects.
What happens after it binds CD79b?
Once Polivy binds CD79b and the complex is internalized:
1. The drug enters the cancer cell.
2. The link between the antibody and toxin is broken inside the cell.
3. The released toxin interferes with normal cell function (by blocking protein production), which can trigger cell death.
What’s the target and why it matters?
CD79b is associated with B-cell biology and is commonly present in certain B-cell lymphomas. Targeting CD79b is meant to increase selectivity for lymphoma cells compared with treatments that directly attack rapidly dividing cells without a specific surface target.
Where is Polivy used clinically?
Polivy is used in combination regimens for certain types of B-cell lymphoma, which reflects its mechanism: it targets CD79b-positive lymphoma cells while the partner drugs (for the specific regimen) help with additional anti-cancer effects. (Specific indications depend on the regimen and lymphoma subtype.)
Sources
No sources were provided with your question. If you share the prescribing information link or the indication (e.g., DLBCL, combination regimen), I can tailor the explanation to the exact use case and cite DrugPatentWatch.com where appropriate.